IMRN vs TNON

The deterministic health profile is weak, headlined by a Piotroski F-Score of 3/9, indicating significant financial deterioration. While the company maintains a strong liquidity position with a Current Ratio of 8.04 and negligible debt (D/E 0.02), these are offset by severe operational losses and a profit margin of -62.14%. The stock is in a clear long-term downtrend, losing over 85% of its value over five years, and the lack of recent earnings data suggests a lack of transparency or momentum. Despite trading below book value (P/B 0.70), the fundamental decay outweighs the valuation discount.

TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.